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Abstract

The human microbiota is paramount for normal host physiology. Altered host-microbiome
interactions are part of the pathogenesis of numerous common ailments. Currently, much
emphasis is placed on the involvement of the microbiome in the pathogenesis of type-2 diabetes
mellitus (T2DM), impaired glucose tolerance, and other metabolic disorders (i.e. obesity). Several
studies found highly significant correlations of specific intestinal bacteria with T2DM. A better
understanding of the role of the microbiome in diabetes and its complications might provide new
insights in the development of new therapeutic principles.
Our pilot study investigates the microbiota patterns in Romanian type-2 diabetic patients with
diabetic kidney disease. Fecal samples were collected from type 2-diabetic patients and healthy
controls and further used for bacterial DNA isolation. Using 16 rDNA qRT-PCR, we analyzed
phyla abundance (Bacteroidetes, Firmicutes) as well as the relative abundance of specific
bacterial groups (Lactobacillus sp., Enterobacteriaceae, Ruminococus sp., Prevotella sp.,
Faecalibacterium sp., Clostridium coccoides, Clostridium leptum). Our study also investigates the
diabetic fungal microbiome for the first time. Furthermore, we report significant correlations
between the treatment regimen and microbiota composition in diabetic nephropathy.

Keywords



Highlights

 This study investigates the changes present in the fungal microbiota of diabetic patients
with diabetic kidney disease, and existing correlations between treatment regimens and
microbiota patterns.

type-2 diabetes, microbiota, microbiome, host-microbiome interactions, dysbiosis

 These preliminary results pave the way for additional studies on larger patient cohorts.
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Introduction
Diabetes is a public health problem affecting
approximately 10% of adults worldwide (1). The
International Diabetes Federation predicts that there will
be 592 million diabetic cases with an additional 175

identified in other currently available studies. For the first
time, our study investigates the fungal microbiota of
diabetic patients.

Materials and Methods

million undiagnosed diabetic cases by 2035 (2). In
Romania, 11.6% of the population aged between 20-79
suffers from diabetes, thus placing our country on the
second place in Europe in terms of diabetic prevalence
(3). This chronic ailment is often complicated by an
increased risk of heart disease, stroke and kidney failure
(4). Diabetic kidney disease, classically defined by the

Patients
The study population (n=9) was represented by
diabetic patients from “N. C. Paulescu” National Institute
of Diabetes, Nutrition and Metabolic Diseases in
Bucharest, Romania, and healthy volunteers. All
participants received and signed the informed consent,
and the Ethical Committee approved the study. All the

presence of proteinuria (macroalbuminuria), is a common
complication most likely to occur in patients with poor
glycemic control, hypertension, glomerular hyperfiltration
or genetic predisposition (5).

enrolled T2D subjects were diagnosed based on the WHO
criteria, namely: polyuria, polydipsia and polyphagia as
well as one of the following: a random venous plasma
glucose concentration ≥ 11.1 mmol/l or a fasting plasma
glucose concentration ≥ 7.0 mmol/l (whole blood ≥ 6.1

Along this line of thinking, there is a growing public
and scientific interest in identifying and modulating the
key factors that govern the onset of diabetes and its

mmol/l) or two hour plasma glucose concentration ≥ 11.1
mmol/l two hours after 75g anhydrous glucose in an oral

complications. Factors such as rapid environmental
changes and modern lifestyle are the major culprits for the
alteration of the intestinal microbiota which controls the
risk of developing metabolic dysfunction. The gut
microbiota is also involved in the development of the
immune system and multiple metabolic pathways.
Therefore, disturbances in its composition and

glucose tolerance test (9).

functionality induced by dietary changes will hinder the
gut barrier function. A disrupted gut barrier permits
passage of microorganisms, microbial products and
foreign antigens into the mucosa subsequently leading to
the immune system activation and secretion of
inflammatory mediators. This low-grade chronic
inflammation induced by a defective gut barrier further

according to the manufacturer’s instructions. Genomic
DNA concentration was determined at a wavelength of
260 nm using a NanoDrop (Thermo Scientific). For qPCR
analysis, DNA samples were diluted in DNAse free water
to a concentration of 3 ng/μl. RT-PCR measured the
relative abundance of intestinal microorganisms in fecal
DNA isolated from T2DM patients and healthy controls

modifies host adiposity and insulin resistance (6). Several

on a ViiA7© Fast Real-Time System.

recent studies have reported changes in the gut microbiota
of individuals at risk of developing diabetes as well as in
already diagnosed patients (7). Even though there has
been no clear microbiota pattern linked to diabetes so far,
it was shown that diabetic individuals generally exhibit
reduced bacterial diversity characterized by a reduction of

DNA samples were amplified using the bacterial or
fungal group-specific primers at their specific annealing
temperatures. Eubacteria primers were used to amplify a
segment of the 16S rDNA in order to determine the total
number of bacteria per sample. The primers used are
listed in Table 1. Each PCR reaction included 200 nM of

butyrate-producing bacteria such as Faecalibacterium

forward and reversed primer, 9 ng of DNA, and 2x SYBR

prausnitzii and Roseburia intestinalis along with an
increase in opportunistic pathogens (pathobionts) (8).

Green Master Mix (Applied Biosystems). Samples
without DNA template served as negative controls.
Samples were incubated at 95ºC for 5 min, and then
amplified through 45 cycles of 95ºC for 10 s, 60ºC for 30
s, and 72ºC for 1 s.

Within this context, our study investigates the
microbiota signatures in Romanian patients with diabetic
nephropathy and compares it with the microbiota patterns

Microbiota analysis
Stool samples were collected at home by the
participants following a standardized procedure including
antiseptic handling, collection in sterile containers and
immediate freezing at −20°C. Fecal DNA was extracted
using the AllPrep PowerViral DNA/RNA (Qiagen)
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Table 1. Primers used in this study
Taxonomic
target

Primer sequence

Eubacteria

UniF340 ACT CCT ACG GGA GGC AGC AGT
UniR514 ATT ACC GCG GCT GCT GGC

Lactobacilli

LabF362 ACG AGT AGG GAA ATC TTC CA
LabR677 CAC CGC TAC ACA TGG AG

Enterobacteriaceae

Uni515F GTG CCA GCM GCC GCG GTAA
Ent826R GCC TCA AGG GCA CAA CCT CCA AG

BPP

Fwd GGTGTCGGCTTAAGTGCCAT
Rev CGGACGTAAGGGCCGTGC

F. prausnitzii

Fwd CCCTTCAGTGCCGCAGT
Rev GTCGCAGGATGTCAAGAC

Bacteroidetes

Bact934F GGAACATGTGGTTTAATTCGATGAT
Bact1060R AGCTGACGACAACCATGCAG

Firmicutes

Firm934F GGAGCATGTGGTTTAATTCGAAGCA
Firm 1060R AGCTGACGACAACCATGCAC

Clostridium leptum

Fwd GCACAAGCAGTGGAGT
Rev CTTCCTCCGTTTTGTCAA

Clostridium
cocoides

Fwd GAC GCC GCG TGA AGG A
Rev AGC CCC AGC CTT TCA CAT C

Ruminococcus

Fwd ACTGAGAGGTTGAACGGCCA
Rev CCTTTACACCCAGTAATTCCGGA

Turicibacter

Fwd CAGACGGGGACAACGATTGGA
Rev TACGCATCGTCGCCTTGGGTA

Fungal 18S

Fwd ATTGGAGGGCAAGTCTGGTG
Rev CCGATCCCTAGTCGGCATAG

Saccharomyces

Fwd AGGAGTGCGGTTCTTTG
Rev TACTTACCGAGGCAAGCTACA

Candida

Fwd TTTATCAACTTGTCACACCAGA
Rev ATCCCGCCTTACCACTACCG

The statistical analysis
The data in our study are presented as mean ± SEM
and were graphed using the GraphPad Prism 5.0 software.
Sample size (n) denotes biological replicates. Differences
in microbial relative abundance were assessed using a
non-parametric Mann-Whitney test. The *p < 0.05 was
considered statistically significant. The statistically
significant levels were *, p < 0.05; **, p < 0.01; ***, p <
0.001.

Results
Our pilot study enrolled 9 T2DM patients with
diabetic nephropathy and 5 healthy controls. Besides
diabetic kidney disease, the enrolled T2DM patients
also suffered from neuropathy (7 patients),
retinopathy (7 patients), osteoporosis (2 patients),
diabetic foot (1 patient), dyslipidemia (8 patients) and
steatosis (6 patients) (Figure 1 A).

fecal microbiota of patients with type-2 diabetes with
that of healthy volunteers using qPCR of the 16S
rRNA gene. qPCR analysis was done using SYBR
Green primers recognizing different phyla such as
Bacteroidetes and Firmicutes, but also bacterial
families
such
as
Lactobacillaceae
and
Enterobacteriaceae. Primers for the Universal
Eubacteria 16S were used for normalization.

Figure 1. Patient characteristics. A. Associated
diabetic complications identified in the enrolled
patients. B. Body mass index differences
between healthy controls and T2DM patients
(Student t-test, p=0.0790)
The total amount of bacteria in the stool samples
are represented as threshold cycle values (Ct) in
Figure 2A. Both healthy controls and T2DM patients
with diabetic nephropathy harbored similar levels of
Eubacteria (Figure 2 A).
The most common organisms in the human gut
microbiota are members of the Gram-positive
Firmicutes and the Gram-negative Bacteroidetes phyla,
followed by several other phyla, including
the Actinobacteria, usobacteria and Verrucomicrobia
(10).
The data from animal models and human studies
have revealed differences in the two dominant
bacterial phyla with a significant increase of
Firmicutes and decrease of Bacteroidetes levels in
obesity (11). Regardless their disease status, the
subjects enrolled in our study had BMI values ranging
from 20 to 38 (Figure 1B), and therefore, there is no

No statistically significant difference was
observed regarding the body mass index (BMI)

surprise that we did not observe significant
differences between Bacteroidetes and Firmicutes
abundance (Figure 2 B-C), even though T2DM

between the two experimental groups (p=0.0790)
(Figure 1 B). In our pilot analysis, we compared the

patients exhibited a tendency to
Firmicutes (Figure 2 C).
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Although the exact role of this butyrate-producing
bacteria in the development of metabolic syndrome is not
known, one study reported an increased abundance
of Turicibacter in the gut of patients with rheumatoid
arthritis, an immune-mediated disease (14).

Figure 2. Microbiota analysis in patients with T2DM
patients with diabetic nephropathy. A. Total bacteria
represented as Ct values obtained from qRT-PCR
targeting the 16S rDNA of all Eubacteria. The
abundance of the Bacteroidetes (B) and Firmicutes (C)
phyla in the stool samples harvested from healthy
individuals (Control) and patients with diabetic
nephropathy (T2DM).
The Bacteroidetes phyla range in relative abundance
among individuals, but generally, make up half or more of
the gut microbiome. The three predominant Bacteroidetes
genera of the human gastrointestinal tract are represented
by Bacteroides, Prevotella, and Porphyromonas (BPP). In
our analysis, no significant differences were observed in
the BPP levels between T2DM patients and healthy
controls (Figure 3 A).
The strictly anaerobic Clostridium coccoides group
constitutes 25% to 60% of the total microbiota and
comprises a large number of species of genera such as
Clostridium, Blautia, Anaerostipes, Ruminococcus, Dorea
Eubacterium and Roseburia (12, 13). In our analysis,
Clostridium coccoides’ relative abundance was similar
between healthy controls and T2DM patients with
diabetic nephropathy (Figure 3B). The qPCR results
indicated that the amounts of Clostridium leptum tended
to be higher in T2DM patients, compared to healthy
controls (Figure 3 C). The Clostridium leptum group of
bacteria (also called Clostridial cluster IV) is a dominant
group of fecal bacteria in adult humans, representing
around 16-25% of the fecal microbiota and it includes
Faecalibacterium prausnitzii and certain species of
Eubacterium and Ruminococcus (13).
Following the same pattern, T2DM patients
exhibited increased levels of Faecalibacterium
prausnitzii and Ruminococcus. No statistically
significant differences were observed between the two
experimental groups regarding the Clostridium leptumRuminococcus-Faecalibacterium prausnitzii levels,
highlighting the need to increase the sample size in a
subsequent study (Figure 3 D, E). The fecal
microbiome of T2DM had significantly higher levels of
Turicibacter sp. (*p= 0.0128) (Figure 3 F).

Figure 3. Microbiota patterns in patients with
T2DM patients with diabetic nephropathy.
Relative abundance of Bacteroides-PrevotellaPorphyromonas (A), Clostridium coccoides (B),
Clostridium leptum (C), Faecalibacterium
prausnitzii (D), Ruminococcus (E) and
Turicibacter (F) in stool samples harvested from
healthy individuals (Control) and patients with
diabetic nephropathy (T2DM).
Interestingly though, T2DM patients harbored a
microbiota enriched in Butyricicoccus spp. Butyricicoccus
members are strictly anaerobic Clostridium cluster IV
bacteria that produce high levels of butyrate (a short fatty
chain of utmost importance for intestinal homeostasis)
and are currently investigated as potential probiotics
(Figure 4A). Under such circumstances, lactobacilli have
also been widely characterized as potent probiotic strains
in numerous studies. Nevertheless, we have tested the
relative abundance of lactobacilli in T2DM patients and
healthy controls, and we did not observe any differences
(Figure 4B).
Oxidative stress and inflammation, especially when
accompanied by obesity, mutually potentiate each other
and promote the onset of beta-pancreatic cell dysfunction,
insulin resistance and T2DM vascular complications. In
accordance with this, several studies have linked
oxidative stress to dysbiosis (15). The intestinal tract
harbors a radical oxygen gradient and hence microbes that
reside in the colonic mucosa exhibit elevated oxygen
tolerance and catalase expression compared to luminal or
stool-associated bacteria (15). Moreover, inflammation
also promotes an oxidative milieu characterized by the
enrichment of aerotolerant phyla such as Proteobacteria
and Actinobacteria. Gut inflammation was reported to be
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responsible for the production of terminal electron
acceptors needed by facultative anaerobes such as
Enterobacteriaceae further augmenting dysbiosis (16, 17).
Specific taxonomic shifts have been linked to intestinal
inflammation, including a relative increase in the
abundance of Enterobacteriaceae, such as Escherichia
coli and Fusobacterium. In our pilot study, the T2DM
microbiota was characterized by significantly higher
levels of Enterobacteriaceae (*p= 0.0238), hence
suggesting a possible link between diabetes and intestinal
inflammation (Figure 4 C).

Figure 4. Relative abundance of Butyricicocus
(A), Lactobacillus (B), and Enterobacteriaceae
(C) in stool samples harvested from healthy
individuals (Control) and patients with diabetic
nephropathy (T2DM).

Compelling recent data reveal the important role that
medication has in triggering changes in the gut
microbiota. For instance, the treatment with metformin
alters the microbiome by promoting the growth of
Akkermansia muciniphila, Lactobacillus sp., Escherichia
spp, and by lowering the levels of Intestinibacter (18).
Bearing this in mind, we tested whether treatment
regimens impact microbiota signatures in diabetic
nephropathy. Of all the T2DM patients tested, 6 patients
(66.6%) received sevelamer carbonate, a phosphate
binding drug prescribed to prevent hyperphosphatemia in
patients with chronic renal failure. Interestingly, the
sevelamer carbonate treatment was significantly
correlated with lower levels of both Enterobacteriaceae
and Turicibacter (Figure 6 A, B).
Importantly, the sevelamer carbonate treatment
decreases levels of potentially pathogenic bacteria
(Enterobacteriaceae), and these results need further
investigation among a larger patient cohort. The other
tested bacterial and fungal populations behaved similarly
regardless of the sevelamer administration.

For the first time, this study also investigates the
differences in the fungal microbiome of diabetic patients
with kidney disease. For this purpose, we quantified the total
amount of fungal DNA in stool samples using universal
primers for fungal 18S rDNA and the relative abundance of
fungal populations such as Candida sp. and Saccharomyces
sp. using specific primers (Figure 5 A-C). We observed no
statistically significant differences regarding the total amount
of fungal DNA sequences or Candida sp. levels. We did,
however, find a tendency for higher levels of Saccharomyces
sp. in T2DM patients but these findings need to be confirmed
among a larger patient cohort.
Figure 6. The sevelamer carbonate treatment
triggers changes in microbiota composition:
Turicibacter sp. (A) and Enterobacteriaceae (B)
are relatively abundant in the stool samples
harvested from healthy individuals (Control) and
patients with diabetic nephropathy (T2DM).

Discussions

Figure 5. Fungal microbiome in diabetic nephropathy:
total abundance of fungal 18SrDNA (expressed as Ct
values), Candida sp. (B) and Saccharomyces sp. (C)
abundance in the stool samples harvested from healthy
individuals (Control) and patients with diabetic
nephropathy (T2DM).
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Human microbiome profiles depend on diet, ethnic
origin, geographic region and age. However, despite these
variables, the microbiome of T2DM patients was
suggested to have some particular features. The
microbiota of T2DM patients has low levels of mucin
degrading bacteria such as Akkermansia sp. and
Prevotella sp. (19) and also butyrate-producing
microorganisms, such as Faecalibacterium prausnitzii,
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Clostridium sp., Roseburia intestinalis, Eubacterium
rectale and Faecalibacterium sp. (20). The human T2DM
intestinal microbiota was shown to be inhabited by
opportunistic pathogens including the sulphate-reducing
genus
Desulfovibrio,
Escherichia
coli
and
Bacteroidaceae. A study performed on Chinese T2DM
patients revealed an increase in Escherichia coli.
Furthermore, a Danish study reported elevated
Proteobacteria in T2DM (21). A study performed on
Romanian subjects revealed that the most common
aerobic/facultative anaerobic species isolated from the
stool cultures of 100 patients with dyslipidemia, diabetes
and obesity were Gram-negative bacteria (22). Our results
are partially in accordance with these studies. Similar to
the study by Larsen et al., we showed that T2DM
microbiota is enriched in Enterobacteriaceae.
In contrast with previously published studies, we
observed that T2DM patients harbored a microbiota
slightly enriched in butyrate-producing microorganisms,
but the difference was not statistically significant. To
address this question, we need to perform further studies
on a larger patient cohort using next-generation
sequencing techniques to ascertain better microbiome
features in T2DM associated with nephropathy. Bacterial
counts of the L. acidophilus, L. plantarum and L. reuteri
subgroups of Lactobacillus sp. were significantly lower
among Romanian patients with T2DM and obesity
compared to healthy controls (23). In our study group, no
differences were seen in case of lactobacilli abundance in
the stool samples harvested from T2DM patients.
However, one must consider that the levels of lactobacilli
inhabiting the microbiota are highly dependent on the
host’s diet.

Conclusions
Herein, we present a pilot study analyzing the
microbiome patterns associated with diabetic nephropathy
in Romanian patients. For the first time, we investigate
the changes present in the fungal microbiota of diabetic
patients with diabetic kidney disease. Besides, we
describe significant correlations between treatment
regimens and microbiota patterns. These preliminary
results pave the way for additional studies on larger
patient cohorts.
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